SA
RXRX icon

Sanctuary Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Sanctuary Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.9K Buy
12,346
+1,858
+18% +$7.18K ﹤0.01% 2505
2025
Q4 		$42.9K Sell
10,488
-2,667
-20% -$13.2K ﹤0.01% 2389
2025
Q3 		$64.2K Sell
13,155
-1,993
-13% -$10.5K ﹤0.01% 2372
2025
Q2 		$76.6K Buy
15,148
+4,653
+44% +$22.9K ﹤0.01% 2285
2025
Q1 		$55.5K Sell
10,495
-1,989
-16% -$14.5K ﹤0.01% 2138
2024
Q4 		$96K Sell
12,484
-1,014
-8% -$6.82K ﹤0.01% 2320
2024
Q3 		$76.9K Buy
+13,498
New +$96.8K ﹤0.01% 2327

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sanctuary Advisors's RXRX Position: Q1 2026 in Review

Sanctuary Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 18% in Q1 2026, buying an estimated $7.18K and bringing the position to 12,346 shares worth $37.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2505.

Sanctuary Advisors first reported a position in RXRX in Q3 2024 and has held it in 7 quarters since. The position peaked at $96K in Q4 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Sanctuary Advisors held 12,346 shares of Recursion Pharmaceuticals worth $37.9K as of Q1 2026.
  • Sanctuary Advisors bought 1,858 Recursion Pharmaceuticals shares in Q1 2026, an estimated $7.18K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Sanctuary Advisors's portfolio in Q1 2026, its #2505 holding.
  • Sanctuary Advisors first reported a position in Recursion Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Sanctuary Advisors's Recursion Pharmaceuticals position peaked at $96K in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Sanctuary Advisors's 13F filing for Q1 2026, filed 5 May 2026.